Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new strategic partnership with US-based Heureka Labs, a spinoff of Duke University, to enhance its gene therapy research using AI technology.
Leire said: “Every biotech in gene therapy should have an AI component. If you don't have that, you miss a critical tool to unlock value for your shareholders.” He stressed the need for a multi-omics approach—genomic, transcriptomic, and proteomic—to better understand gene expression and drug response, which traditional analysis methods struggle to fully capture.
The partnership with Heureka Labs, which integrates deep AI and biological expertise, will initially support Genflow’s lead candidate, GF-1002, a SIRT-6 gene therapy targeting MASH (metabolic dysfunction-associated steatohepatitis). AI will help the company analyse complex preclinical data, including insights from nearly 700 mice tested, to understand mechanisms of action and identify likely responders—crucial in discussions with regulators such as the FDA and EMA.
Leire also emphasised that the collaboration is scalable across Genflow’s pipeline, helping unlock synergies between programmes in liver, muscle, and eye diseases.
For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content.
#GenflowBiosciences #GeneTherapy #AIinBiotech #BiotechNews #MASH #SIRT6 #HeurekaLabs #DrugDevelopment #MultiOmics #BiotechPartnership #FDA #EMA #PreclinicalResearch
